Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

Eric Peter Tamm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9881-1570; OpenAlex author ID A5084420501. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
133
Papers, trials and grants by year

2012: 4 papers · 2013: 1 paper · 2014: 4 papers · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 7 papers · 2019: 4 papers · 2020: 7 papers · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper

Papers 39

  1. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  2. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  3. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  4. Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.1148/rycan.210068↗
  5. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Co-author DOI 10.1186/s12885-021-09095-7↗
  6. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT. Last author DOI 10.1007/s00261-020-02917-5↗
  7. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  8. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Last author DOI 10.1007/s00261-019-02289-5↗
  9. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  10. Pancreatitis and PDAC: association and differentiation. Co-author DOI 10.1007/s00261-019-02292-w↗
  11. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional im… Co-author DOI 10.1007/s00261-020-02723-z↗
  12. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  13. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
  14. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  15. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  16. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  17. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  18. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  19. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  20. Genetics of pancreatic cancer and implications for therapy. Last author DOI 10.1007/s00261-017-1394-y↗
  21. Imaging findings of recurrent pancreatic cancer following resection. Last author DOI 10.1007/s00261-017-1397-8↗
  22. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease. Last author DOI 10.1007/s00261-017-1410-2↗
  23. Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-017-1433-8↗
  24. Introduction to the special section on pancreatic cancer. Co-author DOI 10.1007/s00261-018-1486-3↗
  25. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  26. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  27. ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.jacr.2017.08.050↗
  28. Dual-energy CT of pancreatic adenocarcinoma: reproducibility of primary tumor measurements and assessment of tumor conspicuity and margin sharpness. Last author DOI 10.1007/s00261-016-0689-8↗
  29. Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging. Last author DOI 10.1007/s00261-015-0420-1↗
  30. Quantitative and Qualitative Comparison of Single-Source Dual-Energy Computed Tomography and 120-kVp Computed Tomography for the Assessment of Pancreatic Ducta… Last author DOI 10.1097/rct.0000000000000295↗
  31. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic associatio… Co-author DOI 10.1053/j.gastro.2013.11.004↗
  32. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  33. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Associatio… Co-author DOI 10.1148/radiol.13131184↗
  34. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  35. Imaging of pancreatic ductal adenocarcinoma: State of the art. Co-author DOI 10.4329/wjr.v5.i3.98↗
  36. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Co-author DOI 10.1002/cncr.27636↗
  37. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Co-author DOI 10.1007/s00280-011-1705-x↗
  38. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. Co-author DOI 10.1016/j.jamcollsurg.2012.05.015↗
  39. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Co-author DOI 10.1016/j.rcl.2012.03.008↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Priya Bhosale · 24 shared papers, 2012–2023 · strength 2.04
  2. Matthew H. G. Katz · 21 shared papers, 2012–2022 · strength 1.64
  3. Eugene Jon Koay · 18 shared papers, 2014–2022 · strength 1.48
  4. Robert A. Wolff · 17 shared papers, 2012–2022 · strength 1.21
  5. Gauri Rajani Varadhachary · 15 shared papers, 2012–2022 · strength 1.05
  6. Anirban Maitra · 11 shared papers, 2014–2022 · strength 0.87
  7. Ott Le · 7 shared papers, 2015–2023 · strength 0.71
  8. Huamin Wang · 11 shared papers, 2012–2022 · strength 0.69
  9. Jeffrey E. Lee · 11 shared papers, 2012–2022 · strength 0.63
  10. Jason B. Fleming · 12 shared papers, 2012–2020 · strength 0.63
  11. Sanaz Javadi · 5 shared papers, 2018–2022 · strength 0.63
  12. Erik V. Soloff · 6 shared papers, 2018–2023 · strength 0.59
  13. Mohamed Zaid · 7 shared papers, 2018–2022 · strength 0.56
  14. Marc Zins · 5 shared papers, 2018–2023 · strength 0.52
  15. Avinash R. Kambadakone · 5 shared papers, 2018–2023 · strength 0.49
  16. Ching-Wei David Tzeng · 5 shared papers, 2019–2022 · strength 0.48
  17. Michael P. Kim · 5 shared papers, 2017–2022 · strength 0.43
  18. Christopher H. Crane · 8 shared papers, 2012–2022 · strength 0.41
  19. Zhen J. Wang · 4 shared papers, 2020–2023 · strength 0.41
  20. Milind M. Javle · 7 shared papers, 2014–2022 · strength 0.41
  21. Cullen M. Taniguchi · 5 shared papers, 2018–2022 · strength 0.41
  22. Atif Zaheer · 4 shared papers, 2018–2023 · strength 0.40
  23. Lorenzo Mannelli · 4 shared papers, 2018–2023 · strength 0.39
  24. David R. Fogelman · 6 shared papers, 2012–2020 · strength 0.38
  25. Michael James Overman · 4 shared papers, 2017–2022 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.